{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/cvs-health-cvs/",
 "dataUrl": "https://clearank.com/stock/cvs-health-cvs/data.json",
 "title": "CVS Stock Forecast & Price Target (2026)",
 "description": "CVS Health (CVS) stock analysis: AI price targets, technical signals, valuation and the key risks facing this healthcare giant. Updated daily.",
 "headline": "CVS Health Corporation (CVS)",
 "published": "2026-08-06T09:21:01+00:00",
 "modified": "2026-09-27T02:41:35.244+00:00",
 "generated": "2026-09-27T15:06:58.832Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "CVS",
  "name": "CVS Health Corporation",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Healthcare Plans",
  "country": "United States",
  "website": "https://www.cvshealth.com"
 },
 "quote": {
  "price": 89.13,
  "previousClose": 85.05,
  "change": 4.08,
  "changePercent": 4.8,
  "open": 85.35,
  "high": 89.35,
  "low": 84.7,
  "volume": 15767300,
  "averageVolume": 9531150,
  "marketCap": 113994628988,
  "fiftyTwoWeekHigh": 110.68,
  "fiftyTwoWeekLow": 69.51,
  "marketOpen": false,
  "asOf": "2026-09-27T02:41:35.000Z"
 },
 "statistics": {
  "pe": 23.517149,
  "eps": 3.79,
  "dividendYield": 0.029844048939404563,
  "beta": 0.58,
  "priceToSales": 0.27625352,
  "priceToBook": 1.4291669,
  "revenueTtm": 412644999168,
  "grossMargin": 0.14844103453476098,
  "returnOnEquity": 0.06205
 },
 "technicals": {
  "rsi": 28.32,
  "macd": -2.68,
  "sma50": 97.07,
  "sma200": 87.51,
  "rsiSignal": "Oversold",
  "trend": "Bullish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Sell",
  "score": 21,
  "consensus": "Sell",
  "fairValue": 89.13,
  "analystTarget": 116,
  "analystCount": 27,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-27T02:41:35.000Z",
  "priceAtAnalysis": 89.13,
  "volatility": {
   "daily": 1.67,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bearish",
  "conservativeEntry": 90.91,
  "aggressiveEntry": 89.13,
  "stopLoss": 99.15,
  "stopLossPercent": 9.06,
  "targets": [
   86.37,
   81.82,
   77.28
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 62.75,
    "base": 91.87,
    "upside90th": 134.53
   },
   {
    "year": 2028,
    "downside10th": 55.23,
    "base": 94.7,
    "upside90th": 162.4
   },
   {
    "year": 2029,
    "downside10th": 50.43,
    "base": 97.62,
    "upside90th": 188.97
   },
   {
    "year": 2030,
    "downside10th": 46.93,
    "base": 100.63,
    "upside90th": 215.74
   },
   {
    "year": 2031,
    "downside10th": 44.21,
    "base": 103.73,
    "upside90th": 243.34
   },
   {
    "year": 2032,
    "downside10th": 42.01,
    "base": 106.92,
    "upside90th": 272.1
   },
   {
    "year": 2033,
    "downside10th": 40.19,
    "base": 110.21,
    "upside90th": 302.28
   },
   {
    "year": 2034,
    "downside10th": 38.64,
    "base": 113.61,
    "upside90th": 334.06
   },
   {
    "year": 2035,
    "downside10th": 37.3,
    "base": 117.11,
    "upside90th": 367.63
   },
   {
    "year": 2036,
    "downside10th": 36.14,
    "base": 120.71,
    "upside90th": 403.15
   }
  ]
 },
 "faqCount": 8,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "CVS Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$85.35",
    "Day Range": "$84.70 to $89.35",
    "Prev Close": "$85.05",
    "Volume": "15.77M",
    "52-Week Range": "$69.51 to $110.68",
    "Market Cap": "$113.99B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-26%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "CVS Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, CVS beat estimates 4 times. The stock rose 3 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "CVS Analysis",
   "text": [
    "CVS Health Corporation's stock is currently exhibiting bearish momentum, trading below its 50-day SMA of $97.07 and its 20-day Exponential Moving Average (EMA) of $91.42, though it remains above its 200-day SMA of $87.51. The Relative Strength Index (RSI) is significantly oversold at 28.32, suggesting potential for a short-term bounce, but the MACD at -2.68 indicates a prevailing downward trend. The stock has experienced a significant decline, moving from above its 50-day SMA to below it, signaling a shift in short-term sentiment. Key support levels are being tested, with the 200-day SMA at $87.51 acting as a critical floor. Resistance is now established at the 50-day SMA ($97.07) and the 20-day EMA ($91.42). Volume has been elevated, with the latest volume at 15.77 million, 65.4% above the average, indicating strong selling pressure. The current chart structure points towards continued weakness unless a significant catalyst emerges to reverse the oversold conditions and insider selling trend.",
    "Insiders have sold $577.9 million worth of CVS Health Corporation stock against minimal purchases of $100,000, indicating a strong lack of confidence in the company's future prospects.",
    "The stock's RSI is significantly oversold at 28.32, and it is trading below key moving averages (50-day SMA and 20-day EMA), suggesting potential for further price declines despite the oversold status.",
    "CVS Health Corporation has consistently beaten EPS estimates in recent quarters, demonstrating operational efficiency in meeting or exceeding analyst expectations.",
    "The company's P/E ratio of 23.52 and P/S ratio of 0.28 are below sector medians, suggesting potential undervaluation compared to other healthcare companies.",
    "The base case outlook for CVS Health Corporation over the next 6-12 months is cautious, with the stock facing headwinds from heavy insider selling and oversold technical conditions. While the median analyst price target suggests an upside of 30.1% to $116.00, the current consensus rating is Sell due to these negative signals. The stock's ability to break above its 50-day SMA of $97.07 and sustain momentum will be critical for a bullish reversal. Potential catalysts for a positive shift could include a significant improvement in profit margins, a reversal in insider selling trends, or positive news regarding strategic initiatives. Conversely, continued insider divestiture, failure to break key resistance levels, or worsening profitability could lead to further downside, potentially testing the 200-day SMA at $87.51 and beyond, as indicated by the long-range projection's downside scenario of $46.93 by 2030."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transactions closely; the current heavy selling pressure from officers and directors is a significant bearish signal that overrides positive analyst targets.",
     "Given the oversold RSI of 28.32, traders may look for a short-term bounce, but the prevailing trend and insider activity suggest caution against long positions.",
     "Consider the dividend yield of 2.98% as a potential support, but be aware that the overall negative sentiment and insider selling could impact future dividend sustainability."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold $577.9 million worth of CVS Health Corporation stock against minimal purchases of $100,000, indicating a strong lack of confidence in the company's future prospects.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Oversold Technical Conditions",
     "text": "The stock's RSI is significantly oversold at 28.32, and it is trading below key moving averages (50-day SMA and 20-day EMA), suggesting potential for further price declines despite the oversold status.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bullish",
     "title": "Positive Earnings Surprises",
     "text": "CVS Health Corporation has consistently beaten EPS estimates in recent quarters, demonstrating operational efficiency in meeting or exceeding analyst expectations.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Attractive Valuation Relative to Peers",
     "text": "The company's P/E ratio of 23.52 and P/S ratio of 0.28 are below sector medians, suggesting potential undervaluation compared to other healthcare companies.",
     "source": "Fundamental Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "CVS Health Corporation presents a mixed fundamental picture, with a P/E ratio of 23.52 and a P/S ratio of 0.28 that appear attractive when compared to sector medians of 31.9 and 3.7, respectively. This suggests the stock may be undervalued on a relative basis. However, the company's profitability metrics are concerning, with a Net Profit Margin of 1.18% and an ROE of 6.21%, both significantly below the healthcare sector averages. The Debt-to-Equity ratio of 0.96 is in line with the sector. While the company's valuation multiples are lower than its peers, the lagging profitability and a substantial amount of insider selling raise questions about the sustainability of its current price. The forward revenue growth estimates for the current year are projected at +4.00%, and for next year at +3.00%, indicating modest expansion. The company's ability to improve its profit margins and generate stronger returns will be critical for justifying its current valuation, especially in light of the negative insider sentiment.",
    "CVS Health Corporation recently reported strong EPS beats in its latest quarters, with the quarter to June 2026 showing an actual EPS of $2.58 against an estimate of $1.85, a 39.46% surprise, although the stock reacted negatively with a -2.93% price change. Prior quarters also showed positive surprises, including a 16.29% beat in the quarter to March 2026 and a 16.15% beat in the quarter to December 2025. Despite these consistent earnings beats, the market reaction has been muted or negative, suggesting that the positive earnings surprises are not translating into sustained stock price appreciation.",
    "The most significant risk for CVS Health Corporation is the overwhelming insider selling, with over $577 million in sales against minimal purchases, signaling a strong lack of confidence from management. Additionally, the stock is exhibiting significantly oversold technical conditions with an RSI of 28.32 and is trading below key moving averages, indicating potential for further downside pressure. The company's profitability metrics, including a low net profit margin of 1.18%, also present a risk if they do not improve relative to sector peers."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "113.99B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "23.52"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "3.79"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "2.98%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "110.68"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "69.51"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Oversold SMA Cross Bullish Price vs SMA Bearish MACD Bearish Golden Cross in effect with the 50-day SMA ($97.07) above the 200-day SMA ($87.51), price is trading below the 50-day SMA, RSI at 28.3 suggests oversold conditions; potential bounce setup."
   ],
   "facts": {
    "RSI": "Oversold",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "28.32"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-2.68"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "97.07"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "87.51"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.14",
    "Correlation with Nasdaq 100 (QQQ)": "+0.06",
    "Correlation with Bitcoin (BTC)": "+0.00",
    "Correlation with Gold (XAU)": "-0.02"
   }
  },
  {
   "id": "trade-plans",
   "title": "CVS Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for rally",
    "Higher risk, chasing the move",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (28.3) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$86.37",
    "TARGET 2": "$81.82",
    "TARGET 3": "$77.28",
    "STOP LOSS": "$99.15"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+0.88%",
    "Average Feb return": "-2.12%",
    "Average Mar return": "-2.64%",
    "Average Apr return": "+1.83%",
    "Average May return": "+0.06%",
    "Average Jun return": "+1.85%",
    "Average Jul return": "-0.04%",
    "Average Aug return": "+1.23%",
    "Average Sep return": "+1.90%",
    "Average Oct return": "-2.86%",
    "Average Nov return": "+5.41%",
    "Average Dec return": "-1.93%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.67%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in CVS in September 2016 would be worth about $9,842 today, compared with about $35,782 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CVS today could grow to about $13,543 by 2036 in the base case, with a bull case near $45,231 and a bear case around $4,055. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "CVS Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $101 for CVS by 2030 in the base case, from $89.13 today (1.1x over 4 years). The downside path ends near $46.93. These are outcomes of a Monte Carlo simulation run on CVS's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using CVS's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "CVS simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$62.75",
        "$91.87",
        "$135"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$55.23",
        "$94.70",
        "$162"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$50.43",
        "$97.62",
        "$189"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$46.93",
        "$101",
        "$216"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$44.21",
        "$104",
        "$243"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$42.01",
        "$107",
        "$272"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$40.19",
        "$110",
        "$302"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$38.64",
        "$114",
        "$334"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$37.30",
        "$117",
        "$368"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$36.14",
        "$121",
        "$403"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "MRNA Moderna Inc. NASDAQ $198.88 +2.08%",
     "url": "https://clearank.com/stock/moderna-mrna/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $866.64 -0.31%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    },
    {
     "text": "BDX Becton Dickinson and Co NYSE $183.82 +2.56%",
     "url": "https://clearank.com/stock/bdx-stock-analysis/"
    },
    {
     "text": "VEEV Veeva Systems Inc. NYSE $280.68 +2.12%",
     "url": "https://clearank.com/stock/veev-stock-analysis/"
    },
    {
     "text": "ABT Abbott Laboratories NYSE $101.29 +0.22%",
     "url": "https://clearank.com/stock/abbott-laboratories-abt/"
    },
    {
     "text": "NVO Novo Nordisk A/S Sponsored NYSE $38.80 +0.47%",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $190.86 -1.27%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "IONS Ionis Pharmaceuticals, Inc. NASDAQ $44.50 +1.57%",
     "url": "https://clearank.com/stock/ions-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "GLD vs GDX Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/gld-vs-gdx/"
    },
    {
     "text": "SPY vs VOO Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/spy-vs-voo/"
    },
    {
     "text": "GLD vs SLV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/gld-vs-slv/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "CVS Insider Trading Analysis",
   "facts": {
    "Bought": "$100.0K",
    "Sold": "$577.9M",
    "Insiders": "21",
    "Avg Transaction": "$115.6M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in CVS",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "May 21, 2026",
       "cells": [
        "ROBBINS LARRY Director",
        "Sell",
        "3.4M",
        "$317.5M"
       ]
      },
      {
       "label": "May 6, 2025",
       "cells": [
        "ROBBINS LARRY Director",
        "Sell",
        "3.8M",
        "$253.7M"
       ]
      },
      {
       "label": "Mar 26, 2021",
       "cells": [
        "MERLO LARRY J Director",
        "Sell",
        "270.7K",
        "$20.2M"
       ]
      },
      {
       "label": "Jan 15, 2020",
       "cells": [
        "MERLO LARRY J Chief Executive Officer",
        "Sell",
        "266.5K",
        "$19.9M"
       ]
      },
      {
       "label": "Aug 4, 2022",
       "cells": [
        "LOTVIN ALAN M Officer",
        "Sell",
        "143.4K",
        "$14.2M"
       ]
      },
      {
       "label": "Dec 15, 2022",
       "cells": [
        "MORIARTY THOMAS M General Counsel",
        "Sell",
        "137.5K",
        "$13.5M"
       ]
      },
      {
       "label": "Jun 28, 2022",
       "cells": [
        "MORIARTY THOMAS M General Counsel",
        "Sell",
        "138.7K",
        "$13.2M"
       ]
      },
      {
       "label": "Jan 8, 2019",
       "cells": [
        "MERLO LARRY J Chief Executive Officer",
        "Sell",
        "166.4K",
        "$11.5M"
       ]
      },
      {
       "label": "Feb 1, 2019",
       "cells": [
        "MERLO LARRY J Chief Executive Officer",
        "Sell",
        "166.4K",
        "$10.7M"
       ]
      },
      {
       "label": "Nov 3, 2021",
       "cells": [
        "ROBERTS JONATHAN C Officer",
        "Sell",
        "108.9K",
        "$10.3M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=CVS+Health+Corporation&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is CVS Health Corporation stock a buy right now?",
   "answer": "CVS Health Corporation is currently rated a Sell based on our consensus score of 21, primarily due to heavy insider selling and oversold technicals. While Wall Street analysts maintain a Buy consensus with a median price target of $116.00, the significant negative insider activity and bearish chart patterns suggest caution is warranted."
  },
  {
   "question": "What is CVS Health Corporation's stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, CVS Health Corporation's stock price forecast for 2030 shows a base case of $100.63, with a downside projection of $46.93 and an upside projection of $215.74. These are statistical outcomes and not definitive price targets."
  },
  {
   "question": "What are the biggest risks facing CVS Health Corporation?",
   "answer": "The primary risks for CVS Health Corporation include substantial insider selling exceeding $577 million, which signals a lack of management confidence, and significantly oversold technical conditions with an RSI at 28.3. Also, the company's profit margins are below sector averages, posing a risk to future performance."
  },
  {
   "question": "How does CVS Health Corporation's valuation compare to its sector?",
   "answer": "CVS Health Corporation's P/E ratio of 23.52 and P/S ratio of 0.28 are lower than the healthcare sector medians of 31.9 and 3.7, respectively, suggesting a potentially attractive valuation. However, its ROE of 6.21% and profit margin of 1.18% lag behind sector averages."
  },
  {
   "question": "What is the current technical outlook for CVS Health Corporation stock?",
   "answer": "The technical outlook for CVS Health Corporation is bearish, with the stock trading below its 50-day SMA and 20-day EMA, and showing oversold RSI levels. Key support is at the 200-day SMA of $87.51, while resistance is at the 50-day SMA of $97.07."
  },
  {
   "question": "What is the consensus rating for CVS Health Corporation stock?",
   "answer": "The consensus rating for CVS Health Corporation stock is Sell, with a consensus score of 21 out of 100. This is driven by significant insider selling and bearish technical indicators, despite a generally positive Wall Street analyst consensus."
  },
  {
   "question": "How has CVS Health Corporation performed in recent earnings reports?",
   "answer": "CVS Health Corporation has consistently beaten EPS estimates in recent quarters, including a significant 39.46% surprise in the quarter to June 2026. However, the stock price has reacted negatively to these beats, indicating that earnings performance is not currently driving positive market sentiment."
  },
  {
   "question": "Are there any notable institutional holders or activist investors in CVS Health Corporation?",
   "answer": "While the provided data does not detail specific institutional holders or activist investors, the significant insider selling by officers and directors is a key factor to monitor. The total insider sales amount to $577.9 million, which is a strong signal of potential concern."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "MRNA",
    "name": "Moderna Inc. NASDAQ",
    "price": "$198.88",
    "change": "+2.08%",
    "url": "https://clearank.com/stock/moderna-mrna/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$866.64",
    "change": "-0.31%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   },
   {
    "ticker": "BDX",
    "name": "Becton Dickinson and Co NYSE",
    "price": "$183.82",
    "change": "+2.56%",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   },
   {
    "ticker": "VEEV",
    "name": "Veeva Systems Inc. NYSE",
    "price": "$280.68",
    "change": "+2.12%",
    "url": "https://clearank.com/stock/veev-stock-analysis/"
   },
   {
    "ticker": "ABT",
    "name": "Abbott Laboratories NYSE",
    "price": "$101.29",
    "change": "+0.22%",
    "url": "https://clearank.com/stock/abbott-laboratories-abt/"
   },
   {
    "ticker": "NVO",
    "name": "Novo Nordisk A/S Sponsored NYSE",
    "price": "$38.80",
    "change": "+0.47%",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$190.86",
    "change": "-1.27%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "IONS",
    "name": "Ionis Pharmaceuticals, Inc. NASDAQ",
    "price": "$44.50",
    "change": "+1.57%",
    "url": "https://clearank.com/stock/ions-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "GLD vs GDX Comparison",
    "name": "",
    "url": "https://clearank.com/compare/gld-vs-gdx/"
   },
   {
    "ticker": "SPY vs VOO Comparison",
    "name": "",
    "url": "https://clearank.com/compare/spy-vs-voo/"
   },
   {
    "ticker": "GLD vs SLV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/gld-vs-slv/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "PCAR",
    "text": "PACCAR Inc.",
    "url": "https://clearank.com/stock/pcar-stock-analysis/"
   },
   {
    "ticker": "O",
    "text": "Realty Income Corp.",
    "url": "https://clearank.com/stock/o-stock-analysis/"
   },
   {
    "ticker": "SPG",
    "text": "Simon Property Group Inc.",
    "url": "https://clearank.com/stock/spg-stock-analysis/"
   },
   {
    "ticker": "JCI",
    "text": "Johnson Controls International",
    "url": "https://clearank.com/stock/jci-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "KAS/USD",
    "text": "↑ 11.85%",
    "url": "https://clearank.com/crypto/kaspa-kas-usd/"
   },
   {
    "ticker": "RENDER/USD",
    "text": "↑ 10.19%",
    "url": "https://clearank.com/crypto/render-render-usd/"
   },
   {
    "ticker": "ZS",
    "text": "↓ 10.06%",
    "url": "https://clearank.com/stock/zscaler-zs/"
   },
   {
    "ticker": "MXL",
    "text": "↑ 10.00%",
    "url": "https://clearank.com/stock/mxl-stock-analysis/"
   },
   {
    "ticker": "BE",
    "text": "↑ 8.27%",
    "url": "https://clearank.com/stock/be-stock-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "CI",
    "text": "The Cigna Group",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "CNC",
    "text": "Centene Corporation",
    "url": "https://clearank.com/stock/centene-cnc/"
   },
   {
    "ticker": "ELV",
    "text": "Elevance Health",
    "url": "https://clearank.com/stock/elv-stock-analysis/"
   },
   {
    "ticker": "HUM",
    "text": "Humana Inc",
    "url": "https://clearank.com/stock/hum-stock-analysis/"
   },
   {
    "ticker": "MOH",
    "text": "Molina Healthcare Inc.",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/08/cvs-health-cvs.png",
     "url": "https://clearank.com/wp-content/uploads/2026/08/cvs-health-cvs.png",
     "width": "1280",
     "height": "720",
     "caption": "CVS Health (CVS) stock price analysis chart for August 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/cvs-health-cvs/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/cvs-health-cvs/",
        "name": "CVS Health (CVS) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/cvs-health-cvs/#webpage",
     "url": "https://clearank.com/stock/cvs-health-cvs/",
     "name": "CVS Stock Forecast & Price Target (2026)",
     "datePublished": "2026-08-06T09:21:01+00:00",
     "dateModified": "2026-09-27T02:41:35+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/cvs-health-cvs.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/cvs-health-cvs/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/cvs-health-cvs/#richSnippet",
     "headline": "CVS Stock Forecast & Price Target (2026)",
     "name": "CVS Stock Forecast & Price Target (2026)",
     "description": "CVS Health (CVS) stock analysis: AI price targets, technical signals, valuation and the key risks facing this healthcare giant. Updated daily.",
     "datePublished": "2026-08-06T09:21:01+00:00",
     "dateModified": "2026-09-27T02:41:35+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "CVS Health Corporation",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "CVS"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "CVS Health Corporation Common Stock represents ownership in CVS Health Corporation, a U.S. health solutions company headquartered in Woonsocket, Rhode Island. The company operates across health care benefits, health services, pharmacy, and consumer wellness, serving members, patients, employers, hea",
      "tickerSymbol": "CVS",
      "sameAs": "https://www.cvshealth.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/cvs-health-cvs/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/08/cvs-health-cvs.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/cvs-health-cvs/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is CVS Health Corporation stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "CVS Health Corporation is currently rated a Sell based on our consensus score of 21, primarily due to heavy insider selling and oversold technicals. While Wall Street analysts maintain a Buy consensus with a median price target of $116.00, the significant negative insider activity and bearish chart patterns suggest caution is warranted."
     }
    },
    {
     "@type": "Question",
     "name": "What is CVS Health Corporation's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, CVS Health Corporation's stock price forecast for 2030 shows a base case of $100.63, with a downside projection of $46.93 and an upside projection of $215.74. These are statistical outcomes and not definitive price targets."
     }
    },
    {
     "@type": "Question",
     "name": "What are the biggest risks facing CVS Health Corporation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks for CVS Health Corporation include substantial insider selling exceeding $577 million, which signals a lack of management confidence, and significantly oversold technical conditions with an RSI of 28.32. Also, the company's profit margins are below sector averages, posing a risk to future performance."
     }
    },
    {
     "@type": "Question",
     "name": "How does CVS Health Corporation's valuation compare to its sector?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "CVS Health Corporation's P/E ratio of 23.52 and P/S ratio of 0.28 are lower than the healthcare sector medians of 31.9 and 3.7, respectively, suggesting a potentially attractive valuation. However, its ROE of 6.21% and profit margin of 1.18% lag behind sector averages."
     }
    },
    {
     "@type": "Question",
     "name": "What is the current technical outlook for CVS Health Corporation stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The technical outlook for CVS Health Corporation is bearish, with the stock trading below its 50-day SMA and 20-day EMA, and showing oversold RSI levels. Key support is at the 200-day SMA of $87.51, while resistance is at the 50-day SMA of $97.07."
     }
    },
    {
     "@type": "Question",
     "name": "What is the consensus rating for CVS Health Corporation stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The consensus rating for CVS Health Corporation stock is Sell, with a consensus score of 21 out of 100. This is driven by significant insider selling and bearish technical indicators, despite a generally positive Wall Street analyst consensus."
     }
    },
    {
     "@type": "Question",
     "name": "How has CVS Health Corporation performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "CVS Health Corporation has consistently beaten EPS estimates in recent quarters, including a significant 39.46% surprise in the quarter to June 2026. However, the stock price has reacted negatively to these beats, indicating that earnings performance is not currently driving positive market sentiment."
     }
    },
    {
     "@type": "Question",
     "name": "Are there any notable institutional holders or activist investors in CVS Health Corporation?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "While the provided data does not detail specific institutional holders or activist investors, the significant insider selling by officers and directors is a key factor to monitor. The total insider sales amount to $577.9 million, which is a strong signal of potential concern."
     }
    }
   ]
  }
 ]
}